Cellectis S A 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2025 to a ratio of 6.9, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the fourth quarter 2025. Average receivable collection period, for the Cellectis S A in Dec 31 2025 quarter, has decreased to 53 days, compared to 69 days, in the 0 quarter.

If we take a look into Healthcare sector 541 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2025 from 0 to 3670.

What is Receivable Turnover Ratio?
What is Cellectis S A Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CLLS Receivables Turnover Ratio	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Receivable Change	114.45 %	114.45 %	-9.91 %	114.45 %	1079.96 %
Y / Y Revenue Change	75.76 %	-	107.48 %	-	23217.42 %
Receivable Turnover Ratio (TTM)	6.9	5.26	6.36	5.28	6.63
CLLS's Total Ranking	# 3670	# 0	#	#	#
Accounts Receivable average collection period days	53	69	57	69	55
Seq. Receivable Change	0 %	64.06 %	-39.05 %	114.45 %	0 %
Seq. Revenue Change	-	-	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 60
Healthcare Sector	# 542
Overall Market	# 3670

Receivable Turnover Ratio Statistics
High	Average	Low
24.83	6.29	0.7
(Dec 31 2022)		0

CLLS Company Profile • Back to CLLS Efficiency Comparisons • Compare CLLS Receivables Turnover Ratio to its Competitors

Financial Statements
Cellectis S A 's Accounts Receivable	$ 14 Millions	Visit CLLS's Balance sheet
Cellectis S A 's Sales TTM	$ 90 Millions	Visit CLLS's Income Statement
Sources of CLLS's Revenues		Visit CLLS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
CLLS's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
CLLS's Growth Rates	CLLS's Roa	CLLS's Inventory Turnover Ratio	CLLS's Dividend Comparisons
CLLS's Profitability Ratios	CLLS's Roi	CLLS's Asset Turnover Ratio	CLLS's Dividend Growth
CLLS's Valuation Ratios	CLLS's Roe	CLLS's Financial Strength Ratios	CLLS's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Dec 31 2025	Receivable at quarter ending Dec 31 2025
Marpai Inc	16.64	$ 18.099 Millions	$ 1.088 Millions
Euda Health Holdings Limited	16.07	$ 5.993 Millions	$ 0.373 Millions
Bioage Labs Inc	16.01	$ 8.995 Millions	$ 0.562 Millions
Nutriband Inc	15.64	$ 2.037 Millions	$ 0.130 Millions
Plus Therapeutics Inc	15.53	$ 5.213 Millions	$ 0.336 Millions
Talkspace Inc	15.35	$ 228.871 Millions	$ 14.915 Millions
Nanobiotix S a	15.26	$ 36.504 Millions	$ 2.392 Millions
Gsk Plc	15.21	$ 32,667.000 Millions	$ 2,148.000 Millions
Precipio inc	15.02	$ 24.049 Millions	$ 1.601 Millions
Qhslab Inc	14.47	$ 2.692 Millions	$ 0.186 Millions
Arbutus Biopharma Corp	14.04	$ 14.083 Millions	$ 1.003 Millions
Sutro Biopharma Inc	13.92	$ 102.484 Millions	$ 7.365 Millions
Aim Immunotech Inc	13.54	$ 0.088 Millions	$ 0.007 Millions
Amneal Pharmaceuticals Inc	13.44	$ 3,018.308 Millions	$ 224.629 Millions
Inmed Pharmaceuticals Inc	13.26	$ 4.507 Millions	$ 0.340 Millions
Rosecliff Acquisition Corp I	13.19	$ 20.547 Millions	$ 1.557 Millions
Xoma Royalty Corporation	13.18	$ 52.149 Millions	$ 3.957 Millions
Nexgel Inc	13.17	$ 10.509 Millions	$ 0.798 Millions
China Pharma Holdings Inc	13.14	$ 4.144 Millions	$ 0.315 Millions
Milestone Scientific Inc	12.98	$ 8.408 Millions	$ 0.648 Millions
Escalon Medical Corp	12.93	$ 12.311 Millions	$ 0.952 Millions
Dbv Technologies S a	12.63	$ 5.683 Millions	$ 0.450 Millions
Mannkind Corporation	12.49	$ 348.966 Millions	$ 27.948 Millions
Safe Pro Group Inc	12.46	$ 0.607 Millions	$ 0.049 Millions
Icu Medical Inc	12.35	$ 2,231.262 Millions	$ 180.620 Millions
Ensysce Biosciences Inc	12.27	$ 5.067 Millions	$ 0.413 Millions
Skinhealth Systems Inc	12.08	$ 300.364 Millions	$ 24.872 Millions
Corcept Therapeutics Inc	11.91	$ 761.407 Millions	$ 63.950 Millions
Option Care Health Inc	11.86	$ 5,648.895 Millions	$ 476.492 Millions
Cytokinetics Incorporated	11.74	$ 88.039 Millions	$ 7.499 Millions

Date modified: 2026-07-07T15:09:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.